Scientists at George Mason University’s Center for Applied Proteomics and Molecular Medicine (CAPMM) developed a new technology for testing breast cancer tumors. They used it to discover “novel proteomic-based signatures
/PRNewswire/ Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein.
/PRNewswire/ Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay.
The firm is the latest iteration of the GMU spinout Theranostics Health, which has been working to drive clinical uptake of its technology for over a decade.
E-Mail
IMAGE: Lance Liotta, MD, PhD, study PI, and George Mason University College of Science CAPMM co-founder and co-director. view more
Credit: Evan Cantwell, George Mason University
A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments.
George Mason University s College of Science announced an exciting $1.33 million collaboration with Rutgers Cancer Institute of New Jersey and Mason s Center for Applied Proteomics and Molecular Medicine (CAPMM) which taps cancer research diagnostics and treatment strengths within the medical facilities and CAP/CLIA laboratory respectively of the two regional powerhouses.